Vaccine therapy for cytomegalovirus in the setting of allogeneic hematopoietic cell transplantation

Expert Review of Vaccines

Volumn 14, Issue 3, 2015, Pages 341-350

  Kharfan Dabaja, Mohamed A ^a,b   Nishihori, Taiga ^a,b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

allogeneic hematopoietic cell transplantation; cytomegalovirus; vaccine

Indexed keywords

ASP 0113; BENZIMIDAVIR; BRINCIDOFOVIR; CIDOFOVIR; CYTOMEGALOVIRUS VACCINE; FOSCARNET; GANCICLOVIR; LETERMOVIR; PLACEBO; UNCLASSIFIED DRUG; VALGANCICLOVIR;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CLINICAL STUDY; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; HUMAN; IMMUNOGENICITY; INFECTION PREVENTION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEROLOGY; TREATMENT INDICATION; VIREMIA; VIRUS IMMUNITY; ACTIVE IMMUNIZATION; ADVERSE EFFECTS; ALLOTRANSPLANTATION; CYTOMEGALOVIRUS INFECTIONS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOCOMPROMISED PATIENT; PHASE 3 CLINICAL TRIAL (TOPIC); PROCEDURES; TREATMENT OUTCOME;

CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; CYTOMEGALOVIRUS INFECTIONS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOTHERAPY, ACTIVE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84923107690     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.2015.989990     Document Type: Article

References (92)

1. Kharfan-Dabaja MA, Bazarbachi A. Hematopoietic stem cell allografting for chronic lymphocytic leukemia: a focus on reduced-intensity conditioning regimens. Cancer Contr 2012;19(1):68-75
2. Matos-Fernandez NA, Abou Mourad YR, Caceres W, Kharfan-Dabaja MA. Current status of allogeneic hematopoietic stem cell transplantation for paroxysmal nocturnal hemoglobinuria. Biol Blood Marrow Transplant 2009;15(6):656-61
3. Gooley TA, Chien JW, Pergam SA, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med 2010;363(22):2091-101
4. Kharfan-Dabaja MA, Labopin M, Bazarbachi A, et al. Comparing i.v. BU dose intensity between two regimens (FB2 vs FB4) for allogeneic HCT for AML in CR1: a report from the Acute Leukemia Working Party of EBMT. Bone Marrow Transplant 2014;49(9):1170-5
5. Nishihori T, Perkins J, Mishra A, et al. Pretransplantation 5-azacitidine in high-risk myelodysplastic syndrome. Biol Bone Marrow Transplant 2014;20(6):776-80
6. Sorror ML, Storb RF, Sandmaier BM, et al. Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation. J Clin Oncol 2014;32(29):3249-56
7. Lee SJ, Klein J, Haagenson M, et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood 2007;110(13):4576-83
8. Pidala J, Lee SJ, Ahn KW, et al. Non-permissive-DPB1 mismatch among otherwise HLA-matched donor-recipient pairs results in increased overall mortality after myeloablative unrelated allogeneic hematopoietic cell transplantation for hematologic malignancies. Blood 2014. [Epub ahead of print]
9. Broers AE, van Der Holt R, van Esser JW, et al. Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation. Blood 2000;95(7): 2240-5
10. Meijer E, Dekker AW, Rozenberg-Arska M, et al. Influence of cytomegalovirus seropositivity on outcome after T cell-depleted bone marrow transplantation: contrasting results between recipients of grafts from related and unrelated donors. Clin Infect Dis 2002;35(6):703-12
11. Boeckh M, Nichols WG. The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy. Blood 2004;103(6):2003-8
12. Boeckh M. Complications, diagnosis, management, and prevention of CMV infections: current and future. Hematology Am Soc Hematol Educ Program 2011;2011:305-9
13. Gratwohl A, Brand R, Frassoni F, et al. Cause of death after allogeneic haematopoietic stem cell transplantation (HSCT) in early leukaemias: an EBMT analysis of lethal infectious complications and changes over calendar time. Bone Marrow Transplant 2005;36(9):757-69
14. Fischer SA. Emerging viruses in transplantation: there is more to infection after transplant than CMV and EBV. Transplantation 2008;86(10):1327-39
15. Alford CA, Stagno S, Pass RF, Britt WJ. Congenital and perinatal cytomegalovirus infections. Rev Infect Dis 1990;12(Suppl 7): S745-53
16. Goodrum F, Reeves M, Sinclair J, et al. Human cytomegalovirus sequences expressed in latently infected individuals promote a latent infection in vitro. Blood 2007;110(3): 937-45
17. Reeves MB, MacAry PA, Lehner PJ, et al. Latency, chromatin remodeling, and reactivation of human cytomegalovirus in the dendritic cells of healthy carriers. Proc Natl Acad Sci USA 2005;102(11):4140-5
18. Ariza-Heredia EJ, Nesher L, Chemaly RF. Cytomegalovirus diseases after hematopoietic stem cell transplantation: a mini-review. Cancer Lett 2014;342(1):1-8
19. Boeckh M, Ljungman P. How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood 2009;113(23): 5711-19
20. Boeckh M, Leisenring W, Riddell SR, et al. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood 2003; 101(2):407-14
21. Nichols WG, Price TH, Gooley T, et al. Transfusion-transmitted cytomegalovirus infection after receipt of leukoreduced blood products. Blood 2003;101(10):4195-200
22. Bowden RA, Slichter SJ, Sayers MH, et al. Use of leukocyte-depleted platelets and cytomegalovirus-seronegative red blood cells for prevention of primary cytomegalovirus infection after marrow transplant. Blood 1991;78(1):246-50
23. Bowden RA, Sayers M, Flournoy N, et al. Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation. N Engl J Med 1986;314(16):1006-10
24. Bowden RA, Slichter SJ, Sayers M, et al. A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Blood 1995;86(9): 3598-603
25. Kotton CN. CMV: prevention, diagnosis and therapy. Am J Transplant 2013; 13(Suppl 3):24-40; quiz 40
26. Goodrich JM, Bowden RA, Fisher L, et al. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med 1993; 118(3):173-8
27. Boeckh M, Geballe AP. Cytomegalovirus: pathogen, paradigm, and puzzle. J Clin Invest 2011;121(5):1673-80
28. Hodson EM, Jones CA, Strippoli GF, et al. Immunoglobulins, vaccines or interferon for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev 2007;2:CD005129
29. Alexander BT, Hladnik LM, Augustin KM, et al. Use of cytomegalovirus intravenous immune globulin for the adjunctive treatment of cytomegalovirus in hematopoietic stem cell transplant recipients. Pharmacotherapy 2010;30(6):554-61
30. Chou S, Lurain NS, Thompson KD, et al. Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. J Infect Dis 2003;188(1): 32-9
31. Chemaly RF, Ullmann AJ, Stoelben S, et al. Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation. N Engl J Med 2014;370(19):1781-9
32. Marty FM, Winston DJ, Rowley SD, et al. CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation. N Engl J Med 2013;369(13):1227-36
33. Winston DJ, Young JA, Pullarkat V, et al. Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study. Blood 2008;111(11):5403-10
34. Marty FM, Ljungman P, Papanicolaou GA, et al. Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial. Lancet Infect Dis 2011; 11(4):284-92
35. Fujita Y, Rooney CM, Heslop HE. Adoptive cellular immunotherapy for viral diseases. Bone Marrow Transplant 2008; 41(2):193-8
36. Walter EA, Greenberg PD, Gilbert MJ, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995;333(16):1038-44
37. Einsele H, Roosnek E, Rufer N, et al. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 2002;99(11):3916-22
38. Peggs KS, Verfuerth S, Pizzey A, et al. Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. Lancet 2003;362(9393):1375-7
39. Cobbold M, Khan N, Pourgheysari B, et al. Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J Exp Med 2005;202(3):379-86
40. Micklethwaite K, Hansen A, Foster A, et al. Ex vivo expansion and prophylactic infusion of CMV-pp65 peptide-specific cytotoxic T-lymphocytes following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2007;13(6): 707-14
41. Griffiths PD, Stanton A, McCarrell E, et al. Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. Lancet 2011; 377(9773):1256-63
42. Kharfan-Dabaja MA, Boeckh M, Wilck MB, et al. A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis 2012;12(4):290-9
43. Plotkin SA, Starr SE, Friedman HM, et al. Effect of Towne live virus vaccine on cytomegalovirus disease after renal transplant. A controlled trial. Ann Internal Med 1991;114(7):525-31
44. Selinsky C, Luke C, Wloch M, et al. A DNA-based vaccine for the prevention of human cytomegalovirus-associated diseases. Hum Vaccin 2005;1(1):16-23
45. Wloch MK, Smith LR, Boutsaboualoy S, et al. Safety and immunogenicity of a bivalent cytomegalovirus DNA vaccine in healthy adult subjects. J Infect Dis 2008; 197(12):1634-42
46. Hartikka J, Geall A, Bozoukova V, et al. Physical characterization and in vivo evaluation of poloxamer-based DNA vaccine formulations. J Gene Med 2008;10(7):770-82
47. Kharfan-Dabaja MA, Boeckh M, Wilck MB, et al. Reanalysis of TransVax immunogenicity. Lancet 2013;13(1):18
48. A study to evaluate a therapeutic vaccine, ASP0113, in cytomegalovirus (CMV)-seropositive recipients undergoing allogeneic, hematopoietic cell transplant (HCT) (HELIOS). Available from: http://clinicaltrials.gov/ct2/show/NCT01877655?term=NCT01877655&rank=1
49. Plotkin SA, Higgins R, Kurtz JB, et al. Multicenter trial of Towne strain attenuated virus vaccine in seronegative renal transplant recipients. Transplantation 1994;58(11): 1176-8
50. A study to evaluate the efficacy and safety of a vaccine, ASP0113, in cytomegalovirus (CMV)-seronegative kidney transplant recipients receiving an organ from a cmv-seropositive donor. Available from: http://clinicaltrials.gov/ct2/show/NCT01974206?term=NCT01974206&rank=1
51. Pergam SA, Xie H, Sandhu R, et al. Efficiency and risk factors for CMV transmission in seronegative hematopoietic stem cell recipients. Biol Blood Marrow Transplant 2012;18(9):1391-400
52. Schmidt-Hieber M, Labopin M, Beelen D, et al. CMV serostatus still has an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell transplantation: a report from the Acute Leukemia Working Party of EBMT. Blood 2013;122(19):3359-64
53. Lönnqvist B, Ringdèn O, Ljungman P, et al. Reduced risk of recurrent leukaemia in bone marrow transplant recipients after cytomegalovirus infection. Br J Haematol 1986;63(4):671-9
54. Nachbaur D, Clausen J, Kircher B. Donor cytomegalovirus seropositivity and the risk of leukemic relapse after reduced-intensity transplants. Eur J Haematol 2006;76(5): 414-19
55. Behrendt CE, Rosenthal J, Bolotin E, et al. Donor and recipient CMV serostatus and outcome of pediatric allogeneic HSCT for acute leukemia in the era of CMV-preemptive therapy. Biol Blood Marrow Transplant 2009;15(1):54-60
56. Elmaagacli AH, Steckel NK, Koldehoff M, et al. Early human cytomegalovirus replication after transplantation is associated with a decreased relapse risk: evidence for a putative virus-versus-leukemia effect in acute myeloid leukemia patients. Blood 2011; 118(5):1402-12
57. Green ML, Leisenring WM, Xie H, et al. CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia. Blood 2013;122(7): 1316-24
58. Manjappa S, Bhamidipati PK, Stokerl-Goldstein KE, et al. Protective effect of cytomegalovirus reactivation on relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia patients is influenced by conditioning regimen. Biol Blood Marrow Transplant 2014;20(1):46-52
59. Ljungman P. CMV: a warrior against leukemia? Blood 2013;122(7):1101-2
60. Scheper W, van Dorp S, Kersting S, et al. gdT cells elicited by CMV reactivation after allo-SCT cross-recognize CMV and leukemia. Leukemia 2013;27(6):1328-38
61. Mori T, Mori S, Kanda Y, et al. Clinical significance of cytomegalovirus (CMV) antigenemia in the prediction and diagnosis of CMV gastrointestinal disease after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2004;33(4):431-4
62. Sylwester AW, Mitchell BL, Edgar JB, et al. Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J Exp Med 2005; 202(5):673-85
63. Fouts AE, Chan P, Stephan JP, et al. Antibodies against the gH/gL/UL128/UL130/UL131 complex comprise the majority of the anti-cytomegalovirus (anti-CMV) neutralizing antibody response in CMV hyperimmune globulin. J Virol 2012; 86(13):7444-7
64. Lilleri D, Kabanova A, Revello MG, et al. Fetal human cytomegalovirus transmission correlates with delayed maternal antibodies to gH/gL/pUL128-130-131 complex during primary infection. PLoS One 2013;8(3): e59863
65. Pötzsch S, Spindler N, Wiegers AK, et al. B cell repertoire analysis identifies new antigenic domains on glycoprotein B of human cytomegalovirus which are target of neutralizing antibodies. PLoS Pathog 2011; 7(8):e1002172
66. Huang C, Wang H, Wu S, et al. Comparison of multiple DNA vaccines for protection against cytomegalovirus infection in BALB/c mice. Virol J 2014;11:104
67. Arvin AM, Fast P, Myers M, et al. Vaccine development to prevent cytomegalovirus disease: report from the National Vaccine Advisory Committee. Clin Infect Dis 2004; 39(2):233-9
68. La Rosa C, Longmate J, Lacey SF, et al. Clinical evaluation of safety and immunogenicity of PADRE-cytomegalovirus (CMV) and tetanus-CMV fusion peptide vaccines with or without PF03512676 adjuvant. J Infect Dis 2012; 205(8):1294-304
69. Horn B, Bao L, Dunham K, et al. Infusion of cytomegalovirus specific cytotoxic T lymphocytes from a sero-negative donor can facilitate resolution of infection and immune reconstitution. Pediatr Infect Dis J 2009;28(1):65-7
70. Zhou W, Longmate J, Lacey SF, et al. Impact of donor CMV status on viral infection and reconstitution of multifunction CMV-specific T cells in CMV-positive transplant recipients. Blood 2009;113(25):6465-76
71. Storek J, Dawson MA, Lim LC, et al. Efficacy of donor vaccination before hematopoietic cell transplantation and recipient vaccination both before and early after transplantation. Bone Marrow Transplant 2004;33(3):337-46
72. Wald A, Selke S, Magaret A, Boeckh M. Impact of human cytomegalovirus (CMV) infection on immune response to pandemic 2009 H1N1 influenza vaccine in healthy adults. J Med Virol 2013;85(9):1557-60
73. MK-8228 (Letermovir) Versus Placebo in the Prevention of Clinically-Significant Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients (MK-8228-001). Available from: http://clinicaltrials.gov/show/NCT02137772 [Last accessed 25 September 2014]
74. A study of the safety and efficacy of CMX001 for the prevention of cytomegalovirus (CMV) infection in CMV-seropositive (R+) hematopoietic stem cell transplant recipients. Available from: http://clinicaltrials.gov/show/NCT01769170 [Last accessed 25 September] [2014]
75. Eiz-Vesper B, Maecker-Kolhoff B, Blasczyk R. Adoptive T-cell immunotherapy from third-party donors: characterization of donors and set up of a T-cell donor registry. Front Immunol 2012;3:410
76. Cytomegalovirus (CMV) vaccine in donors and recipients undergoing allogeneic hematopoietic cell transplant (HCT). Available from: http://clinicaltrials.gov/show/NCT00285259
77. An evaluation of a cytomegalovirus (CMV) vaccine (ASP0113) in CMV-seropositive and CMV-seronegative healthy subjects and CMV-seronegative dialysis patients. Available from: http://clinicaltrials.gov/ct2/show/NCT02103426?term=NCT02103426&rank=1
78. A study to evaluate safety and tolerability of a therapeutic vaccine, ASP0113, in subjects undergoing allogeneic hematopoietic cell transplant. Available from: http://clinicaltrials.gov/ct2/show/NCT01903928?term=NCT01903928&rank=1
79. CMV glycoprotein B vaccine in allograft recipients. Available from: http://clinicaltrials.gov/ct2/show/NCT00299260?term=NCT00299260&rank=1
80. GB/MF59 vaccine in preventing cytomegalovirus infection in healthy adolescent females. Available from: http://clinicaltrials.gov/show/NCT00133497
81. Recombinant CMV gB Vaccine in postpartum women. Available from: http://clinicaltrials.gov/ct2/show/NCT00125502?term=NCT00125502&rank=1
82. Study to evaluate safety and immunogenicity of the GSK bio CMV vaccine in CMV-seronegative healthy male adult subjects. Available from: clinicaltrials.gov/ct2/show/NCT00435396?term=NCT00435396&rank=1
83. Accelerated immunization to induce cytomegalovirus immunity in stem cell donors. Available from: http://clinicaltrials.gov/ct2/show/NCT00353977?term=NCT00353977&rank=1
84. Vaccine therapy in healthy volunteers with or without previous exposure to cytomegalovirus. Available from: http://clinicaltrials.gov/show/NCT01941056
85. Vaccine therapy in preventing cytomegalovirus in healthy participants. Available from: http://clinicaltrials.gov/ct2/show/NCT00722839?term=NCT00722839&rank=1
86. Vaccine therapy in preventing cytomegalovirus infection in patients with hematological malignancies undergoing donor stem cell transplant. Available from: http://clinicaltrials.gov/ct2/show/NCT01588015?term=NCT01588015&rank=1
87. A clinical trial of an alphavirus replicon vaccine for cytomegalovirus (CMV). Available from: clinicaltrials.gov/ct2/show/NCT00439803?term=NCT00439803&rank=1
88. Safety, tolerability, and immunogenicity of the human cytomegalovirus vaccine (V160) in healthy adults (V160-001). Available from: http://clinicaltrials.gov/ct2/show/NCT01986010?term=NCT01986010&rank=1
89. Trial of pDNA CMV Vaccine (VCL-CT02) Followed by Towne CMV Vaccine (Towne) Challenge. Available from: http://clinicaltrials.gov/ct2/show/NCT00373412?term=NCT00373412&rank=1
90. Phase 1 trial of CMV towne vaccine in subjects previously received VCL CT02 vaccine ID or IM. Available from: http://clinicaltrials.gov/ct2/show/NCT00370006?term=NCT00370006&rank=1
91. Evaluation of the immunogenicity and efficacy of the towne strain of CMV in seronegative women. Available from: http://clinicaltrials.gov/ct2/show/NCT00201448?term=NCT00201448&rank=1
92. Safety study of four chimera cytomegalovirus (CMV) vaccines in healthy adult males 30-50 years of age. Available from: http://clinicaltrials.gov/ct2/show/NCT01195571?term=NCT01195571&rank=1